Krystal Biotech Receives FDA Approval For First-Ever Redosable Gene Therapy, VYJUVEK For Treatment Of Dystrophic Epidermolysis Bullosa
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has received FDA approval for its first-ever redosable gene therapy, VYJUVEK, for the treatment of Dystrophic Epidermolysis Bullosa (DEB). The topical gel addresses the genetic cause of DEB by restoring functional copies of the COL7A1 gene. The Phase 3 trial met its primary and secondary endpoints, and the company will host an investor conference call on May 19, 2023.
May 19, 2023 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's FDA approval for VYJUVEK, a first-ever redosable gene therapy for DEB treatment, may positively impact the company's stock price.
The FDA approval of VYJUVEK is a significant milestone for Krystal Biotech, as it is the first-ever redosable gene therapy for DEB treatment. This approval may lead to increased investor confidence and demand for the company's stock, resulting in a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100